keyword
MENU ▼
Read by QxMD icon Read
search

lopinavir

keyword
https://www.readbyqxmd.com/read/28528404/a-direct-comparison-of-the-effects-of-the-antiretroviral-drugs-stavudine-tenofovir-and-the-combination-lopinavir-ritonavir-on-bone-metabolism-in-a-rat-model
#1
M M Conradie, M van de Vyver, E Andrag, M Conradie, W F Ferris
Antiretroviral (ARV) treatment may induce metabolic complications in HIV patients on long-term therapy that can affect bone health. In this study, the effects of the ARVs Stavudine (d4T), Tenofovir (TDF) and Lopinavir/ritonavir (LPV/r) on bone metabolism and lipodystrophy were directly compared in rats to negate the consequences of HIV-associated confounding factors. Healthy 12-14-week-old male Wistar rats (n = 40) were divided into four treatment groups and received an oral animal equivalent dose of either Stavudine (6...
May 20, 2017: Calcified Tissue International
https://www.readbyqxmd.com/read/28499879/developing-a-flexible-pediatric-dosage-form-for-antiretroviral-therapy-a-fast-dissolving-tablet
#2
Manjari Lal, Manshun Lai, Marcus Estrada, Changcheng Zhu
Current presentations of the anti-HIV drugs lopinavir and ritonavir make appropriate dosing for children difficult. We conducted a feasibility study to develop a formulation for these drugs with child-safe excipients in a flexible dosage form for children across the pediatric age spectrum. The freeze-drying-in-blister approach was used to produce fast-dissolving tablets (FDTs), as these can be dispersed in fluids for easy administration, even to infants, and appropriate portions of the dispersion can be given for different ages/weights...
May 9, 2017: Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/28495562/nucleoside-reverse-transcriptase-inhibitor-cross-resistance-and-outcomes-from-second-line-antiretroviral-therapy-in-the-public-health-approach-an-observational-analysis-within-the-randomised-open-label-earnest-trial
#3
Nicholas I Paton, Cissy Kityo, Jennifer Thompson, Immaculate Nankya, Leonard Bagenda, Anne Hoppe, James Hakim, Andrew Kambugu, Joep J van Oosterhout, Mary Kiconco, Silvia Bertagnolio, Philippa J Easterbrook, Peter Mugyenyi, A Sarah Walker
BACKGROUND: Cross-resistance after first-line antiretroviral therapy (ART) failure is expected to impair activity of nucleoside reverse-transcriptase inhibitors (NRTIs) in second-line therapy for patients with HIV, but evidence for the effect of cross-resistance on virological outcomes is limited. We aimed to assess the association between the activity, predicted by resistance testing, of the NRTIs used in second-line therapy and treatment outcomes for patients infected with HIV. METHODS: We did an observational analysis of additional data from a published open-label, randomised trial of second-line ART (EARNEST) in sub-Saharan Africa...
May 8, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28489856/randomized-trial-of-stopping-or-continuing-art-among-postpartum-women-with-pre-art-cd4-%C3%A2-400-cells-mm3
#4
Judith S Currier, Paula Britto, Risa M Hoffman, Sean Brummel, Gaerolwe Masheto, Esau Joao, Breno Santos, Linda Aurpibul, Marcelo Losso, Marie F Pierre, Adriana Weinberg, Devasena Gnanashanmugam, Nahida Chakhtoura, Karin Klingman, Renee Browning, Anne Coletti, Lynne Mofenson, David Shapiro, Jose Pilotto
BACKGROUND: Health benefits of postpartum antiretroviral therapy (ART) for human immunodeficiency virus (HIV) positive women with high CD4+ T-counts have not been assessed in randomized trials. METHODS: Asymptomatic, HIV-positive, non-breastfeeding women with pre-ART CD4+ T-cell counts ≥ 400 cells/mm3 started on ART during pregnancy were randomized up to 42 days after delivery to continue or discontinue ART. Lopinavir/ritonavir plus tenofovir/emtricitabine was the preferred ART regimen...
2017: PloS One
https://www.readbyqxmd.com/read/28486519/changes-in-body-mass-index-and-hemoglobin-concentration-in-breastfeeding-women-living-with-hiv-with-a-cd4-count-over-350-results-from-4-african-countries-the-anrs-12174-trial
#5
Eric Nagaonlé Somé, Ingunn M S Engebretsen, Nicolas Nagot, Nicolas Y Meda, Roselyne Vallo, Chipepo Kankasa, James K Tumwine, Mandisa Singata, Justus G Hofmeyr, Philippe Van de Perre, Thorkild Tylleskär
INTRODUCTION: Breastfeeding is recommended for infants born to HIV-infected women in low-income settings. Both breastfeeding and HIV-infection are energy demanding. Our objective was to explore how exclusive and predominant breastfeeding changes body mass index (BMI) among breastfeeding HIV1-positive women participating in the ANRS12174 trial (clinical trial no NCT0064026). METHODS: HIV-positive women (n = 1 267) with CD4 count >350, intending to breastfeed HIV-negative infants were enrolled from Burkina Faso, South Africa, Uganda and Zambia and counselled on breastfeeding...
2017: PloS One
https://www.readbyqxmd.com/read/28481997/patterns-of-growth-body-composition-and-lipid-profiles-in-a-south-african-cohort-of-human-immunodeficiency-virus-infected-and-uninfected-children-a-cross-sectional-study
#6
Sarah M Ramteke, Stephanie Shiau, Marc Foca, Renate Strehlau, Francoise Pinillos, Faeezah Patel, Avy Violari, Afaaf Liberty, Ashraf Coovadia, Louise Kuhn, Stephen M Arpadi
Background.: Prior research in sub-Saharan Africa reports dyslipidemia in perinatally human immunodeficiency virus (HIV)-infected children receiving ritonavir-boosted lopinavir (LPV/r) compared with efavirenz; however, interpretation of findings is limited by lack of comparison data from HIV-uninfected children. Methods.: We conducted a cross-sectional analysis of lipid profiles and growth within a larger longitudinal cohort study of perinatally HIV-infected and HIV-uninfected children aged 4-9 years in Johannesburg, South Africa...
May 6, 2017: Journal of the Pediatric Infectious Diseases Society
https://www.readbyqxmd.com/read/28480762/steady-state-pharmacokinetics-of-tenofovir-disoproxil-fumarate-in-human-immunodeficiency-virus-infected-chinese-patients
#7
Xiaoli Du, Huijuan Kou, Qiang Fu, Yanling Li, Zhu Zhu, Taisheng Li
BACKGROUND: The pharmacokinetic (PK) profile of tenofovir disoproxil fumarate in Chinese adults infected with HIV is unknown. RESEARCH DESIGN AND METHODS: A pilot, prospective, open-label study was performed to investigate the steady-state PK profile of tenofovir disoproxil fumarate in 15 Chinese HIV-infected patients among whom eight patients were treated with 300 mg tenofovir disoproxil fumarate, 300 mg lamivudine and 400/100 mg lopinavir/ritonavir, and seven with 300 mg tenofovir disoproxil fumarate, 300 mg lamivudine and 400 mg nevirapine...
May 8, 2017: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/28475554/sustained-viral-suppression-in-hiv-infected-children-on-once-daily-lopinavir-ritonavir-in-clinical-practice
#8
Ivar P E Gondrie, Diane E T Bastiaans, Pieter L A Fraaij, Gertjan J A Driessen, Linda C Van Der Knaap, Eline G Visser, Petronette Van Jaarsveld, Ronald de Groot, Nico G Hartwig, David M Burger, Annemarie M C Van Rossum
BACKGROUND: The use of lopinavir/ritonavir once-daily (LPV/r QD) has not been approved for children. Good short-term clinical, virological and immunological outcomes have been observed in children on LPV/r QD. METHODS: We evaluated the long-term effectiveness of a LPV/r QD containing regimen in HIV-1 infected children in clinical practice. Selected children (aged 0-18 years) with an undetectable HIV-1 RNA viral load (<50 copies/mL) for at least 6 months on a twice-daily (BID) LPV/r-containing regimen switched to LPV/r QD...
May 4, 2017: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/28463882/impact-of-intensified-antiretroviral-therapy-during-early-hiv-infection-on-gut-immunology-and-inflammatory-blood-biomarkers-a-randomized-controlled-trial
#9
Connie J Kim, Rodney Rousseau, Sanja Huibner, Colin Kovacs, Erika Benko, Kamnoosh Shahabi, Gabor Kandel, Mario Ostrowski, Rupert Kaul
OBJECTIVE: Standard antiretroviral therapy (ART) is slow to reverse gut mucosal immune defects that cause persistent inflammation and immune activation. We examined whether intensifying early-administered ART through the addition of maraviroc and raltegravir would accelerate their resolution. DESIGN: ART-naïve men with early HIV infection were randomized in a double-blind manner to receive ART (emtricitabine/tenofovir disoproxil fumarate + lopinavir/ritonavir), together with either combined raltegravir/maraviroc or placebo, for 48 weeks...
May 1, 2017: AIDS
https://www.readbyqxmd.com/read/28458904/fluticasone-furoate-induced-iatrogenic-cushing-syndrome-in-a-pediatric-patient-receiving-anti-retroviral-therapy
#10
S A A van den Berg, N E van 't Veer, J M A Emmen, R H T van Beek
SUMMARY: We present a case of iatrogenic Cushing's syndrome, induced by treatment with fluticasone furoate (1-2 dd, 27.5 µg in each nostril) in a pediatric patient treated for congenital HIV. The pediatric patient described in this case report is a young girl of African descent, treated for congenital HIV with a combination therapy of Lopinavir/Ritonavir (1 dd 320/80 mg), Lamivudine (1 dd 160 mg) and Abacavir (1 dd 320 mg). Our pediatric patient presented with typical Cushingoid features (i...
2017: Endocrinology, Diabetes & Metabolism Case Reports
https://www.readbyqxmd.com/read/28453240/virological-response-and-resistances-over-12-months-among-hiv-infected-children-less-than-two-years-receiving-first-line-lopinavir-ritonavir-based-antiretroviral-therapy-in-cote-d-ivoire-and-burkina-faso-the-monod-anrs-12206-cohort
#11
Clarisse Amani-Bosse, Désiré Lucien Dahourou, Karen Malateste, Madeleine Amorissani-Folquet, Malik Coulibaly, Sophie Dattez, Arlette Emieme, Mamadou Barry, Christine Rouzioux, Sylvie N'gbeche, Caroline Yonaba, Marguerite Timité-Konan, Véronique Mea, Sylvie Ouédraogo, Stéphane Blanche, Nicolas Meda, Carole Seguin-Devaux, Valériane Leroy
INTRODUCTION: Lopinavir/ritonavir-based antiretroviral therapy (ART) is recommended for all HIV-infected children less than three years. However, little is known about its field implementation and effectiveness in West Africa. We assessed the 12-month response to lopinavir/ritonavir-based antiretroviral therapy in a cohort of West African children treated before the age of two years. METHODS: HIV-1-infected, ART-naive except for a prevention of mother-to-child transmission (PMTCT), tuberculosis-free, and less than two years of age children with parent's consent were enrolled in a 12-month prospective therapeutic cohort with lopinavir/ritonavir ART and cotrimoxazole prophylaxis in Ouagadougou and Abidjan...
April 25, 2017: Journal of the International AIDS Society
https://www.readbyqxmd.com/read/28447585/metabolic-profiles-of-individuals-switched-to-second-line-antiretroviral-therapy-after-failing-standard-first-line-therapy-for-treatment-of-hiv-1-infection-in-a-randomized-controlled-trial
#12
Amanda H Yao, Cecilia L Moore, Poh Lian Lim, Jean-Michel Molina, Juan Sierra Madero, Stephen Kerr, Paddy Wg Mallon, Sean Emery, David A Cooper, Mark A Boyd
BACKGROUND: To investigate metabolic changes associated with second-line antiretroviral therapy (ART) following virological failure of first-line ART. METHODS: SECOND-LINE was an open-label randomized controlled trial. Participants were randomized 1:1 to receive ritonavir-boosted lopinavir (LPV/r) with 2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI-group) or raltegravir (RAL-group) Two hundred and ten participants had a dual energy X-ray absorptiometry (DXA)-scan at baseline, week 48 and 96...
April 27, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/28434406/efavirenz-based-simplification-after-successful-early-lopinavir-boosted-ritonavir-based-therapy-in-hiv-infected-children-in-burkina-faso-and-c%C3%A3-te-d-ivoire-the-monod-anrs-12206-non-inferiority-randomised-trial
#13
Désiré Lucien Dahourou, Madeleine Amorissani-Folquet, Karen Malateste, Clarisse Amani-Bosse, Malik Coulibaly, Carole Seguin-Devaux, Thomas Toni, Rasmata Ouédraogo, Stéphane Blanche, Caroline Yonaba, François Eboua, Philippe Lepage, Divine Avit, Sylvie Ouédraogo, Philippe Van de Perre, Sylvie N'Gbeche, Angèle Kalmogho, Roger Salamon, Nicolas Meda, Marguerite Timité-Konan, Valériane Leroy
BACKGROUND: The 2016 World Health Organization guidelines recommend all children <3 years start antiretroviral therapy (ART) on protease inhibitor-based regimens. But lopinavir/ritonavir (LPV/r) syrup has many challenges in low-income countries, including limited availability, requires refrigeration, interactions with anti-tuberculous drugs, twice-daily dosing, poor palatability in young children, and higher cost than non-nucleoside reverse transcriptase inhibitor (NNRTI) drugs. Successfully initiating LPV/r-based ART in HIV-infected children aged <2 years raises operational challenges that could be simplified by switching to a protease inhibitor-sparing therapy based on efavirenz (EFV), although, to date, EFV is not recommended in children <3 years...
April 24, 2017: BMC Medicine
https://www.readbyqxmd.com/read/28419200/switching-to-efavirenz-versus-remaining-on-ritonavir-boosted-lopinavir-in-hiv-infected-children-exposed-to-nevirapine-long-term-outcomes-of-a-randomized-trial
#14
Pamela M Murnane, Renate Strehlau, Stephanie Shiau, Faeezah Patel, Ndileke Mbete, Gillian Hunt, Elaine J Abrams, Ashraf Coovadia, Louise Kuhn
Background: We previously demonstrated the non-inferiority of switching to efavirenz (EFV) versus remaining on ritonavir-boosted lopinavir (LPV/r) for virologic control in HIV-infected children exposed to nevirapine (NVP) for prevention of mother-to-child transmission. Here we assess outcomes up to four years post-randomization. Methods: From 2010-2013, 298 NVP-exposed HIV-infected children ≥3 years of age were randomized to switch to EFV or remain on LPV/r in Johannesburg, South Africa (Clinicaltrials...
April 17, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/28403052/second-and-third-line-antiretroviral-therapy-for-children-and-adolescents-a-scoping-review
#15
REVIEW
Erica Lazarus, Simone Nicol, Lisa Frigati, Martina Penazzato, Mark F Cotton, Elizabeth Centeno-Tablante, Avy Violari, Liesl Nicol
BACKGROUND: The World Health Organization identified a need for evidence to inform revision of second- and third-line antiretroviral therapy (ART) options in children failing ART. We performed an in-depth scoping review of all available literature on second-line and subsequent ART regimens in children younger than 18 years. METHODS: We comprehensively searched, without language or date limitations, the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, the World Health Organization's International Clinical Trials Registry Platform and ClinicalTrials...
May 2017: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/28398959/emergence-of-untreatable-multidrug-resistant-hiv-1-in-patients-failing-second-line-therapy-in-kenya
#16
Seth C Inzaule, Raph L Hamers, Irene Mukui, Kennedy Were, Prestone Owiti, Daniel Kwaro, Tobias F Rinke de Wit, Clement Zeh
: We performed a countrywide assessment of HIV drug resistance among 123 patients with virological failure on second-line antiretroviral therapy (ART) in Kenya. The percentage of patients harboring intermediate-to-high-level resistance was 27% for lopinavir-ritonavir, 24% for atazanavir-ritonavir and 7% for darunavir-ritonavir, and 25% had complete loss of activity to all available first- and second-line drugs. Overall, one in four patients failing second-line ART have completely exhausted available antiretrovirals in Kenya, highlighting the need for increased access to third-line drugs...
April 10, 2017: AIDS
https://www.readbyqxmd.com/read/28389458/probable-interaction-between-levothyroxine-and-ritonavir-case-report-and-literature-review
#17
Rahul Sahajpal, Rabia A Ahmed, Christine A Hughes, Michelle M Foisy
PURPOSE: A case of probable interaction of levothyroxine and ritonavir is presented along with a review of the relevant literature and recommendations on clinical management. SUMMARY: A 37-year-old woman with human immunodeficiency virus infection who had recently undergone thyroidectomy for a benign multinodular goiter presented to a clinic with hypothyroidism (she was also found to be pregnant), and treatment with levothyroxine 75 μg daily was initiated. While receiving antiretroviral therapy (abacavir-lamivudine and lopinavir-ritonavir) during pregnancy, the patient had persistently elevated serum thyroid-stimulating hormone (TSH) concentrations (up to 125...
April 15, 2017: American Journal of Health-system Pharmacy: AJHP
https://www.readbyqxmd.com/read/28377050/deciphering-the-effects-of-nelfinavir-and-lopinavir-on-epimastigote-forms-of-trypanosoma-cruzi
#18
Leandro Stefano Sangenito, Arthur A de Guedes, Diego S Gonçalves, Sergio H Seabra, Claudia M d'Avila-Levy, André L S Santos, Marta H Branquinha
No abstract text is available yet for this article.
April 1, 2017: Parasitology International
https://www.readbyqxmd.com/read/28376824/hepatitis-c-co-infection-is-associated-with-an-increased-risk-of-incident-chronic-kidney-disease-in-hiv-infected-patients-initiating-combination-antiretroviral-therapy
#19
Carmine Rossi, Janet Raboud, Sharon Walmsley, Curtis Cooper, Tony Antoniou, Ann N Burchell, Mark Hull, Jason Chia, Robert S Hogg, Erica E M Moodie, Marina B Klein
BACKGROUND: Combination antiretroviral therapy (cART) has reduced mortality from AIDS-related illnesses and chronic comorbidities have become prevalent among HIV-infected patients. We examined the association between hepatitis C virus (HCV) co-infection and chronic kidney disease (CKD) among patients initiating modern antiretroviral therapy. METHODS: Data were obtained from the Canadian HIV Observational Cohort for individuals initiating cART from 2000 to 2012. Incident CKD was defined as two consecutive serum creatinine-based estimated glomerular filtration (eGFR) measurements <60 mL/min/1...
April 4, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28369381/randomized-controlled-trial-of-the-tolerability-and-completion-of-maraviroc-compared-with-kaletra%C3%A2-in-combination-with-truvada%C3%A2-for-hiv-post-exposure-prophylaxis-mipep-trial
#20
Ana Milinkovic, Paul Benn, Alejandro Arenas-Pinto, Nataliya Brima, Andrew Copas, Amanda Clarke, Martin Fisher, Gabriel Schembri, David Hawkins, Andy Williams, Richard Gilson
Objectives: Post-exposure prophylaxis (PEP) for HIV is often poorly tolerated and not completed. Alternative PEP regimens may improve adherence and completion, aiding HIV prevention. We conducted a randomized controlled trial of a maraviroc-based PEP regimen compared with a standard-of-care regimen using ritonavir-boosted lopinavir. Methods: Patients meeting criteria for PEP were randomized to tenofovir disoproxil/emtricitabine (200/245 mg) once daily plus ritonavir-boosted lopinavir (Kaletra ® 400/100 mg) or maraviroc 300 mg twice daily...
June 1, 2017: Journal of Antimicrobial Chemotherapy
keyword
keyword
114248
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"